beta
Trial Radar AI
Clinical Trial NCT07501819 for Ventricular Tachycardia (VT) is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Sympathetic Ablation for Ventricular Arrhythmias 10

Not yet recruiting
Clinical Trial NCT07501819 is an interventional study for Ventricular Tachycardia (VT) and is currently not yet recruiting. Enrollment is planned to begin on April 1, 2026 and continue until the study accrues 10 participants. Led by SymKardia, this study is expected to complete by September 1, 2027. The latest data from ClinicalTrials.gov was last updated on March 30, 2026.
Brief Summary
Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.
Detailed Description
The autonomic nervous system controls cardiac activity, and sympathetic hyperactivity is an important factor in triggering and sustaining cardiac arrhythmias such as ventricular tachycardia (VT). The objective of this study is to evaluate a new treatment for VT that targets a specific nerve that is part of the sympathetic system. In an acute procedure, an ablation catheter will be inserted into the femoral artery and...Show More
Official Title

Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias

Conditions
Ventricular Tachycardia (VT)
Other Study IDs
  • SK-001
NCT ID Number
NCT07501819
Start Date (Actual)
2026-04
Last Update Posted
2026-03-30
Completion Date (Estimated)
2027-09
Enrollment (Estimated)
10
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalTherapy
Central sympathetic nerve ablation therapy
Central sympathetic nerve ablation
Catheter-based ablation of an extra-cardiac nerve target
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Freedom from device and procedure-related serious adverse events (SAEs)
3 months
VT burden (episodes per month)
VT burden post-ablation will be compared to VT burden pre-ablation
3 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Age 18 or older at the time of informed consent
  2. Willing and capable of providing written informed consent
  3. Implanted ICD or CRT-D
  4. Recurrent VT leading to ICD therapy (ATP or shock)
  5. Indicated for catheter ablation of VT per international guidelines
  6. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia

  1. Contraindication to percutaneous femoral arterial access
  2. Heparin-induced thrombotic thrombocytopenia
  3. Prior surgical sympathectomy
  4. ECMO therapy in the past 30 days
  5. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)
  6. A most recently documented LVEF <20% in the past 30 days
  7. Receiving inotropic drug therapy
  8. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment
  9. A life expectancy of less than 12 months according to physician judgment
  10. Involvement in any concurrent clinical study with an investigational therapy
SymKardia logoSymKardia
Study Central Contact
Contact: Imad Libbus, PhD, 651-242-4431, [email protected]
No location data.